Thanks for posting this abstract along with that from the NUCLEAR (938/7977) study. Roche may continue to push forward with the outdated PROPEL study in the hope (very unlikely IMO) that PSI-7977 stumbles on safety. Starting the GT2/3 trial would prove this program still has legs. I like the name (mericitabine) but I doubt it's a name anyone will remember in the next 10 years.
I'm still waiting to hear more on INFORM-SVR. In this case I feel no news is bad news for Roche.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.